NL180009C - Farmaceutisch preparaat met anti-bacteriele en beta-lactamase remmende werking alsmede met een heterocyclische vijfring gecondenseerd 2-azetidinon. - Google Patents

Farmaceutisch preparaat met anti-bacteriele en beta-lactamase remmende werking alsmede met een heterocyclische vijfring gecondenseerd 2-azetidinon.

Info

Publication number
NL180009C
NL180009C NLAANVRAGE7806126,A NL7806126A NL180009C NL 180009 C NL180009 C NL 180009C NL 7806126 A NL7806126 A NL 7806126A NL 180009 C NL180009 C NL 180009C
Authority
NL
Netherlands
Prior art keywords
azetidinone
heterocyclic
bacterial
condensed
beta
Prior art date
Application number
NLAANVRAGE7806126,A
Other languages
English (en)
Dutch (nl)
Other versions
NL7806126A (nl
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27122691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL180009(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NL7806126A publication Critical patent/NL7806126A/xx
Application granted granted Critical
Publication of NL180009C publication Critical patent/NL180009C/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NLAANVRAGE7806126,A 1977-06-07 1978-06-06 Farmaceutisch preparaat met anti-bacteriele en beta-lactamase remmende werking alsmede met een heterocyclische vijfring gecondenseerd 2-azetidinon. NL180009C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80432077A 1977-06-07 1977-06-07
US87938178A 1978-02-21 1978-02-21

Publications (2)

Publication Number Publication Date
NL7806126A NL7806126A (nl) 1978-12-11
NL180009C true NL180009C (nl) 1986-12-16

Family

ID=27122691

Family Applications (2)

Application Number Title Priority Date Filing Date
NLAANVRAGE7806126,A NL180009C (nl) 1977-06-07 1978-06-06 Farmaceutisch preparaat met anti-bacteriele en beta-lactamase remmende werking alsmede met een heterocyclische vijfring gecondenseerd 2-azetidinon.
NL930064C NL930064I2 (nl) 1977-06-07 1993-06-11 Farmaceutisch preparaat met anti-bacteriële en beta-lactamase remmende werking alsmede met een hetero-cyclische vijfring gecondenseerd 2-azetidinon.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL930064C NL930064I2 (nl) 1977-06-07 1993-06-11 Farmaceutisch preparaat met anti-bacteriële en beta-lactamase remmende werking alsmede met een hetero-cyclische vijfring gecondenseerd 2-azetidinon.

Country Status (35)

Country Link
AR (1) AR224111A1 (ko)
AT (2) AT360649B (ko)
AU (1) AU513636B2 (ko)
BE (1) BE867859A (ko)
BG (2) BG34614A3 (ko)
CH (1) CH634073A5 (ko)
CS (1) CS208472B2 (ko)
DD (2) DD148585A5 (ko)
DE (2) DE2824535C3 (ko)
DK (1) DK155740C (ko)
EG (1) EG13869A (ko)
FI (1) FI66003C (ko)
FR (2) FR2393804A1 (ko)
GB (1) GB2000138B (ko)
GR (1) GR72255B (ko)
HK (1) HK13184A (ko)
HU (1) HU180042B (ko)
IE (1) IE47079B1 (ko)
IL (2) IL54867A (ko)
IN (1) IN149747B (ko)
IT (1) IT1096381B (ko)
KE (1) KE3355A (ko)
LU (1) LU79774A1 (ko)
MY (1) MY8500092A (ko)
NL (2) NL180009C (ko)
NO (2) NO151746C (ko)
NZ (1) NZ187476A (ko)
OA (1) OA05964A (ko)
PH (3) PH26810A (ko)
PL (1) PL114501B1 (ko)
PT (1) PT68146A (ko)
SE (2) SE436206B (ko)
SG (1) SG65383G (ko)
SU (1) SU860706A1 (ko)
YU (1) YU41829B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77306A1 (ko) * 1977-05-09 1979-01-18
DE2912511C2 (de) * 1977-06-07 1982-06-24 Pfizer Inc., 10017 New York, N.Y. Pharmazeutische Zusammensetzung, enthaltend Penicillansäure
DK155942C (da) * 1977-12-23 1989-10-23 Pfizer Analogifremgangsmaade til fremstilling af 6-aminopenicillansyre-1,1-dioxid og fysiologisk acceptable syreadditions- og basesalte deraf.
JPS54126735A (en) * 1978-03-24 1979-10-02 Toyama Chem Co Ltd Bactericidal composition for medical use
US4241050A (en) * 1978-09-01 1980-12-23 Pfizer Inc. Penam 1,1-dioxides as beta-lactamase inhibitors
CA1158639A (en) * 1978-12-11 1983-12-13 Eric M. Gordon 6-bromopenicillanic acid sulfone
IE49880B1 (en) * 1979-02-13 1986-01-08 Leo Pharm Prod Ltd Penicillin derivatives
SE449103B (sv) * 1979-03-05 1987-04-06 Pfizer Sett att framstella penicillansyra-1,1-dioxid samt estrar derav
US4714761A (en) * 1979-03-05 1987-12-22 Pfizer Inc. 6,6-dihalopenicillanic acid 1,1-dioxides and process
US4420426A (en) 1979-03-05 1983-12-13 Pfizer Inc. 6-Alpha-halopenicillanic acid 1,1-dioxides
GB2045236A (en) * 1979-03-26 1980-10-29 Hoechst Uk Ltd Oxapenem derivatives
US4244951A (en) 1979-05-16 1981-01-13 Pfizer Inc. Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide
US4309347A (en) * 1979-05-16 1982-01-05 Pfizer Inc. Penicillanoyloxymethyl penicillanate 1,1,1',1'-tetraoxide
IE49770B1 (en) * 1979-05-21 1985-12-11 Leo Pharm Prod Ltd 6beta-halopenicillanic acid derivatives
DE3051044C2 (ko) * 1979-06-19 1989-03-30 Leo Pharmaceutical Products Ltd. A/S (Loevens Kemiske Fabrik Produktionsaktieselskab), Ballerup, Dk
US4256733A (en) * 1979-09-26 1981-03-17 Pfizer Inc. Acetoxymethyl penam compounds as β-lactamase inhibitors
US4432970A (en) * 1979-11-23 1984-02-21 Pfizer Inc. 6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
IL61880A (en) * 1980-01-21 1984-11-30 Bristol Myers Co 2beta-chloromethyl-2alpha-methylpenam-3alpha-carboxylic acid sulfone derivatives,their preparation and pharmaceutical compositions containing them
US4488994A (en) * 1980-09-08 1984-12-18 Pfizer Inc. Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide
US4432903A (en) * 1980-09-08 1984-02-21 Pfizer Inc. Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide
US4474698A (en) * 1980-12-11 1984-10-02 Pfizer Inc. Process for preparing esters of penicillanic acid sulfone
US4419284A (en) * 1981-03-23 1983-12-06 Pfizer Inc. Preparation of halomethyl esters (and related esters) of penicillanic acid 1,1-dioxide
EP0069962B1 (en) * 1981-07-15 1985-01-02 Kanebo, Ltd. Novel ester of 1,1-dioxopenicillanic acid, process for production thereof, and use thereof as beta-lactamase inhibitor
PT76526B (en) * 1982-04-19 1986-01-21 Gist Brocades Nv Preparation of 6-alpha-bromo- and/or 6,6-dibromopenicillanic acid 1,1-dioxides
US4502988A (en) * 1983-08-08 1985-03-05 Eli Lilly And Company Oxidation process
EP0139047A1 (en) * 1983-10-18 1985-05-02 Gist-Brocades N.V. Process for the preparation of 6,6-dibromopenicillanic acid 1,1-dioxide
US4647457A (en) * 1983-12-16 1987-03-03 Hoffmann-La Roche Inc. Penicillanic acid derivatives
JPH07103129B2 (ja) * 1986-04-10 1995-11-08 レオ・ファーマシューティカル・プロダクツ・リミテッド・エイ/エス(レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクチーセルスカブ) ペニシラン酸誘導体の改良された新規合成方法
GB8808701D0 (en) * 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
CN102977120B (zh) * 2012-12-14 2015-05-27 江西富祥药业股份有限公司 一种舒巴坦匹酯制备及结晶方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197466A (en) * 1961-10-30 1965-07-27 Smith Kline French Lab Penicillin sulfoxides and process
LU77306A1 (ko) * 1977-05-09 1979-01-18
AU3796278A (en) * 1977-07-13 1980-01-17 Glaxo Group Ltd Penams and azetidinones

Also Published As

Publication number Publication date
GB2000138B (en) 1982-03-03
DK155740C (da) 1989-10-23
AT360649B (de) 1981-01-26
DE2824535B2 (de) 1980-05-14
FR2393805B1 (ko) 1984-02-24
AT364084B (de) 1981-09-25
SE447995B (sv) 1987-01-12
YU41829B (en) 1988-02-29
PH16465A (en) 1983-10-20
PL114501B1 (en) 1981-02-28
DD140888A5 (de) 1980-04-02
FR2393805A1 (fr) 1979-01-05
FI781800A (fi) 1978-12-08
IL62168A0 (en) 1981-03-31
FI66003B (fi) 1984-04-30
HK13184A (en) 1984-02-24
DK251478A (da) 1978-12-08
IT1096381B (it) 1985-08-26
SE8305916L (sv) 1983-10-27
LU79774A1 (fr) 1980-01-22
AU513636B2 (en) 1980-12-11
DD148585A5 (de) 1981-06-03
GB2000138A (en) 1979-01-04
NL930064I2 (nl) 1994-04-18
NO823126L (no) 1978-12-08
CS208472B2 (en) 1981-09-15
BG34615A3 (en) 1983-10-15
IT7824270A0 (it) 1978-06-06
NL7806126A (nl) 1978-12-11
IL54867A (en) 1981-11-30
IE781140L (en) 1978-12-07
SE7806628L (sv) 1978-12-08
HU180042B (en) 1983-01-28
SE8305916D0 (sv) 1983-10-27
BG34614A3 (en) 1983-10-15
IL54867A0 (en) 1978-08-31
ATA411278A (de) 1980-06-15
NZ187476A (en) 1982-08-17
CH634073A5 (en) 1983-01-14
DE2824535C3 (de) 1981-01-22
DE2824535A1 (de) 1978-12-14
PH26810A (en) 1992-11-05
IN149747B (ko) 1982-04-03
NO781970L (no) 1978-12-08
DK155740B (da) 1989-05-08
SG65383G (en) 1985-03-29
IE47079B1 (en) 1983-12-14
FR2393804A1 (fr) 1979-01-05
NO151746C (no) 1985-06-05
ATA128580A (de) 1981-02-15
BE867859A (fr) 1978-12-06
AU3683878A (en) 1979-12-06
FR2393804B1 (ko) 1980-11-07
SU860706A1 (ru) 1981-08-30
OA05964A (fr) 1981-06-30
NO152448B (no) 1985-06-24
NO152448C (no) 1985-10-02
NO151746B (no) 1985-02-18
SE436206B (sv) 1984-11-19
DE2857263B2 (de) 1981-04-23
AR224111A1 (es) 1981-10-30
GR72255B (ko) 1983-10-06
YU117078A (en) 1983-01-21
PH21116A (en) 1987-07-16
DE2857263C3 (de) 1981-12-17
FI66003C (fi) 1984-08-10
KE3355A (en) 1983-12-16
PT68146A (en) 1978-07-01
EG13869A (en) 1983-03-31
MY8500092A (en) 1985-12-31
NL930064I1 (nl) 1993-09-01
PL207396A1 (pl) 1979-06-04

Similar Documents

Publication Publication Date Title
NL180009C (nl) Farmaceutisch preparaat met anti-bacteriele en beta-lactamase remmende werking alsmede met een heterocyclische vijfring gecondenseerd 2-azetidinon.
NL183358C (nl) Farmaceutisch preparaat, en daarin te gebruiken penicillaanzuur-derivaat met beta-lactamase-remmende werking.
NL7801996A (nl) Chinazolineverbindingen met anti-hypertensieve werking.
NL185622C (nl) Farmaceutisch preparaat met antibacteriele werking, alsmede 7beta-acylamino-7alfa-methoxy-3-heterocyclylthiomethyl-3-cefem-4-carbonzuur.
NL7700712A (nl) Azetidinonderivaten met anti-bacteriele werking.
NL191777C (nl) Gelyofiliseerd farmaceutisch preparaat met anti-bacteriële werking.
NL173750C (nl) Farmaceutisch preparaat met prostaglandine-antagonistische werking alsmede daarin bruikbare monocyclische organische verbindingen.
NL185923B (nl) Farmaceutisch preparaat met antibacteriele werking, alsmede penam-3-carbonzuur-1,1-dioxyde-derivaat.
AT370486B (de) Schliesszylinder od.dgl.
NL190632C (nl) Oxadethiacefalosporinen en geneesmiddel met antibacteriële werking.
DE3873996D1 (de) Heterozyklische pestizidverbindungen.
NL7803897A (nl) Afrasteringselement voor een veiligheidsafrastering.
DE69017970D1 (de) Biozide Verbindungen.
NL180511C (nl) Farmaceutisch preparaat met antibacteriele werking, alsmede 7beta-(2-(4-alkyl-2,3-dioxopiperazine-1-ylcarbonylamino)acetylamino)-3-(gesubstitueerd methyl)-3-cefem-4-carbonzuur derivaat.
DE69017971D1 (de) Biozide Verbindungen.
DE69016122D1 (de) Biozide Verbindungen.
AT361657B (de) Kippsicherung, auszugssperre od.dgl.
NL191171C (nl) Tablet met aritmie-bestrijdende werking.
DE3854544D1 (de) Pestizide Verbindungen.
NL7800313A (nl) Motorisch aangedreven slagboom.
BR7701680A (pt) Compostos organicos,composicoes herbicidas e sua aplicaca
NL170855C (nl) Geneesmiddelen met werking tegen atheroma en de daarin voorkomende pyrimidinederivaten.
NL7801204A (nl) Indanderivaat met analgetische werking.
NL7802474A (nl) Geneesmiddel met hypolipidemierende werking.
ES242606Y (es) Llave perfeccionada.

Legal Events

Date Code Title Description
BB A search report has been drawn up
BC A request for examination has been filed
A85 Still pending on 85-01-01
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 19980606